Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia A

NCT03003533 is registered in ClinicalTrials.gov with Spark Therapeutics, Inc. as lead sponsor.

NCT NCT03003533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03003533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gene-transfer, Open-label, Dose-escalation Study of SPK-8011 [Adeno-associated Viral Vector With B-domain Deleted Human Factor VIII Gene] in Individuals With Hemophilia A
Lead sponsor
Spark Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
January 26, 2017
Completion date
December 5, 2023
Enrollment
25 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a